Retatrutide is an investigational triple agonist medication generating significant interest for obesity and type 2 diabetes management. If you are asking how much retatrutide you should take, it is essential to understand that retatrutide is not currently approved by the MHRA or EMA for use in the United Kingdom. There is no officially sanctioned dosing regimen for routine clinical use. This article explains what retatrutide is, how it works, who has been studied in clinical trials, its potential side effects, and — most importantly — how to access safe, evidence-based weight management treatments that are already available to you in the UK.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously; it is not approved by the MHRA or EMA and has no licensed dosing regimen for routine UK clinical use.

Retatrutide is an investigational medication currently undergoing clinical trials for the management of obesity and type 2 diabetes. It belongs to a novel class of drugs known as triple agonists, meaning it simultaneously activates three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple mechanism distinguishes it from existing approved treatments such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GIP/GLP-1 agonist).

By activating these three pathways together, retatrutide is thought to produce effects on appetite suppression and blood glucose regulation. The glucagon receptor component is hypothesised to enhance energy expenditure and fat breakdown, which researchers believe may contribute to greater weight loss compared with dual or single agonists — though this remains under investigation and has not been definitively established. In the Phase 2 trial published in the New England Journal of Medicine (2023), participants receiving retatrutide achieved substantial reductions in body weight over 24 weeks, with higher doses associated with mean weight losses of approximately 17% of body weight; however, these are early-phase findings and longer-term data are awaited.

In clinical trials, retatrutide has been administered as a once-weekly subcutaneous injection, with a structured dose-escalation schedule used to improve tolerability. There is no approved dosing regimen for routine clinical use.

It is important to understand that retatrutide is not currently approved for use in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). It remains under investigation and is not available as a licensed prescription medicine. Therefore, there is no officially approved dosing guidance for general clinical use at this time. Any information circulating online about specific doses should be treated with considerable caution, as self-administering unlicensed substances carries serious health risks.

Who May Be Suitable for Retatrutide Treatment?

Retatrutide has no formally approved patient population in the UK; clinical trials enrolled adults with obesity or overweight plus comorbidities, or type 2 diabetes, but self-sourcing the unlicensed drug is strongly discouraged.

Because retatrutide has not yet received regulatory approval in the UK, there is currently no defined patient population for whom it is formally indicated. However, based on the clinical trial criteria used in studies such as the Phase 2 trial published in the New England Journal of Medicine (2023), researchers have investigated its use in adults with:

• Obesity, defined as a body mass index (BMI) of 30 kg/m² or above

• Overweight (BMI 27 kg/m² or above) with at least one weight-related comorbidity, such as hypertension, dyslipidaemia, or obstructive sleep apnoea

• Type 2 diabetes, where improved glycaemic control alongside weight reduction is a treatment goal

In clinical trials, participants were typically adults without a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). It is worth noting that for currently licensed GLP-1 receptor agonists in the UK, the thyroid tumour signal is classified as a precautionary consideration based on rodent data, rather than a formal contraindication — as reflected in UK Summaries of Product Characteristics (SmPCs). The trial exclusion criteria for retatrutide reflect a similar precautionary approach and should not be interpreted as a confirmed risk in humans.

For patients currently seeking weight management support in the UK, NICE-approved pathways remain the appropriate route. NICE guidance (TA875) supports the use of semaglutide 2.4 mg (Wegovy) for adults with a BMI of 35 kg/m² or above alongside at least one weight-related condition, within a specialist weight management service (with lower BMI thresholds applicable for certain ethnic groups and other commissioning criteria). Tirzepatide is MHRA-authorised as Mounjaro for type 2 diabetes and as Zepbound for weight management; however, NHS access for weight management depends on NICE guidance and local commissioning decisions, and availability varies. Those who believe they may benefit from emerging treatments like retatrutide in the future should discuss this with their GP or a specialist, who can advise on clinical trial eligibility or monitor developments in licensing.

Self-sourcing unlicensed medicines is strongly discouraged and may be unsafe.

Potential Side Effects and Safety Considerations

The most common side effects are gastrointestinal — including nausea, vomiting, and diarrhoea — and are most pronounced during dose escalation; additional concerns include heart rate increases, pancreatitis, and gallbladder disease.

As with other incretin-based therapies, retatrutide has been associated with a range of side effects in clinical trials. The most commonly reported adverse effects are gastrointestinal in nature and include:

• Nausea (particularly during dose escalation)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects are generally dose-dependent and tend to be most pronounced during the initial weeks of treatment when the dose is being gradually increased. In trials, a structured dose-escalation schedule was used specifically to minimise gastrointestinal tolerability issues.

The addition of glucagon receptor agonism introduces some theoretical safety considerations not seen with GLP-1 agonists alone. Increases in heart rate have been observed in some trial participants, which warrants monitoring in individuals with pre-existing cardiovascular conditions. Effects on blood pressure are less clear; blood pressure may decrease alongside weight loss, and any cardiovascular effects should be interpreted in the context of overall trial data rather than assumed to be adverse.

As a class effect shared with GLP-1 receptor agonists, there is a precautionary concern regarding thyroid C-cell tumours, based on animal studies. This has not been confirmed in humans, and UK SmPCs for licensed GLP-1 receptor agonists classify this as a precaution rather than a contraindication. Pancreatitis has also been reported with GLP-1-based therapies; patients should seek urgent medical attention if they experience severe or persistent abdominal pain.

Gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), has been observed with incretin-based therapies. Patients should seek prompt medical advice if they develop right upper abdominal pain, fever, or jaundice.

Severe vomiting or diarrhoea can lead to dehydration and, in some cases, acute kidney injury. It is important to maintain adequate fluid intake and to seek medical attention if you experience significantly reduced urine output or symptoms of severe dehydration.

For people with type 2 diabetes who are also taking insulin or sulfonylureas, there is an increased risk of hypoglycaemia (low blood sugar). A clinician may need to review and adjust these medicines if retatrutide or a similar agent is introduced.

Important safety note: Because retatrutide is unlicensed in the UK, there is no MHRA-approved Summary of Product Characteristics or monitoring recommendations for routine clinical use, and there is no regulated supply chain. Obtaining it through unregulated online sources significantly increases the risk of receiving counterfeit, contaminated, or incorrectly dosed products. The MHRA has issued repeated warnings about the dangers of purchasing unlicensed weight loss injections online.

If you experience any suspected side effects from any medicine — licensed or otherwise — you can report these to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Speaking to a Healthcare Professional About Your Options

Speak to your GP before considering retatrutide; licensed UK options include orlistat, semaglutide 2.4 mg (Wegovy), and tirzepatide (Mounjaro), and your GP can also advise on clinical trial eligibility.

If you are considering retatrutide or have questions about how much you should take, the most important step is to speak with your GP or a qualified healthcare professional before taking any action. Retatrutide is not routinely available or prescribed in the UK outside of clinical trials, and there are no legitimate supply routes for general clinical use at this time. Attempting to self-administer an unlicensed substance without medical supervision is potentially dangerous and may also delay access to safe, effective, and evidence-based treatments that are already available.

Your GP can assess your individual circumstances, including your BMI, medical history, and any existing conditions, to determine which licensed weight management options may be appropriate for you. Currently available options in the UK include:

• Orlistat – a licensed oral medication available on prescription or over the counter

• Semaglutide 2.4 mg (Wegovy) – a once-weekly injection approved by NICE (TA875) for eligible patients within a specialist weight management service

• Tirzepatide (Mounjaro) – MHRA-authorised for type 2 diabetes; also authorised as Zepbound for weight management, though NHS access for weight management depends on NICE guidance and local commissioning decisions

• Referral to a Tier 3 or Tier 4 specialist weight management service for more complex cases

If you are interested in participating in a clinical trial involving retatrutide or similar investigational medicines, your GP may be able to refer you to a research centre. The primary UK resource for finding eligible trials is the NIHR Be Part of Research portal (bepartofresearch.nihr.ac.uk), which lists NHS-supported studies. You can also search the ClinicalTrials.gov database for international studies.

It is entirely understandable to feel frustrated if existing treatments have not met your expectations. However, patient safety must remain the priority. A healthcare professional can help you navigate your options, set realistic expectations, and ensure that any treatment you receive is appropriate, monitored, and as safe as possible. Never adjust or initiate any medication — licensed or otherwise — without professional guidance.

Frequently Asked Questions